Pyroptosis is not the quiet, tidy death that cells usually undergo. In apoptosis, a cell dismantles itself into membrane-wrapped fragments that are cleared without stirring the immune system. Pyroptosis is the opposite: gasdermin proteins form pores in the cell membrane, the cell swells and bursts, and its contents spill into the surrounding tissue, triggering inflammation. GSDME, one of the key executors of this process, can be activated by caspase-3, the very enzyme that drives apoptosis, effectively acting as a molecular switch between the two death pathways. Because of this dual identity, GSDME has attracted intense interest in cancer biology, where inflammatory cell death can either alert immune cells to a tumor or, paradoxically, feed the inflammatory environment that tumors exploit.

To determine which role GSDME plays in gastric cancer, the research team, led by Yeqiong Xu, Yaoyao Zhuang, and Huanhuan Chen of the Center Laboratory of Changshu Medical Examination Institute, together with colleagues at Changshu Hospital Affiliated to Nanjing University of Chinese Medicine and Affiliated Changshu Hospital of Nantong University, combined large-scale computational analysis with laboratory experiments. They mined data from The Cancer Genome Atlas, a comprehensive public repository of tumor genomes and clinical information, using the Xiantao Academic Online analysis tool to compare GSDME expression between tumor tissue and healthy stomach tissue. The results were unambiguous: GSDME was significantly upregulated in stomach adenocarcinoma, and patients whose tumors expressed higher levels of the protein tended to have more advanced disease and poorer survival.

The computational findings were then validated at the protein level in real tissue samples. Using western blotting, a technique that separates proteins by molecular weight and detects them with specific antibodies, and immunohistochemistry, which visualizes protein distribution in stained tissue sections under a microscope, the researchers confirmed that GSDME accumulates in gastric cancer tissue. This two-pronged approach, pairing population-scale bioinformatics with direct protein measurement, strengthens the case that the elevation of GSDME is a genuine feature of gastric tumors rather than an artifact of sequencing data or statistical noise.

But the most intriguing part of the study concerns what GSDME is doing inside the tumor microenvironment. When the researchers stratified the TCGA stomach adenocarcinoma cohort by GSDME expression and ran gene set enrichment analysis, a method that tests whether predefined groups of genes are overrepresented in high versus low expression tumors, they found that tumors with high GSDME were enriched for genes involved in immunosuppressive pathways. In other words, the very protein associated with worse outcomes was also associated with the molecular machinery that helps tumors hide from immune attack.

Deeper immune profiling reinforced that picture. Analyzing the data with R software and the Tumor-Immune System Interactions and Drug Bank database, known as TISIDB, the team found that GSDME expression was positively correlated with immune cell infiltration into tumors, as well as with the expression of immune checkpoint molecules such as PD-1 pathway components, lymphocyte markers, immunomodulators, and major histocompatibility complex molecules. At first glance, more immune infiltration might sound like good news, since it suggests the immune system has noticed the tumor. Yet the coupling of infiltration with checkpoint expression and immunosuppressive signaling suggests a more troubling scenario: an inflamed but functionally suppressed tumor microenvironment, in which immune cells are present but held in check, a state that often predicts resistance to immunotherapy and more aggressive disease.

To test whether GSDME directly influences cancer cell behavior, the researchers turned to functional experiments in two gastric cancer cell lines, AGS and MKN-45. When they knocked down GSDME using RNA interference techniques, the cells became less proliferative and less migratory, two hallmarks of malignancy, while simultaneously showing increased cell death. This result is striking because it inverts the conventional expectation that inducing cell death in cancer cells is always beneficial. Here, reducing a cell death executor made the cancer cells behave less aggressively, implying that in gastric cancer, GSDME may be supporting tumor growth and spread rather than restraining them.

That interpretation fits with a growing body of evidence that GSDME’s role in cancer is far from one-dimensional. Recent studies have shown that full-length GSDME can mediate pyroptosis without being cleaved, that nuclear GSDME can drive metastatic progression independently of pyroptosis, and that in some cancers, including hepatocellular carcinoma, glioblastoma, and pancreatic adenocarcinoma, GSDME appears to promote tumor survival or resistance to treatment. In pancreatic cancer, for example, GSDME has been linked to resistance of tumor cells to enzymatic digestion through a mucin-related pathway. The new gastric cancer data now add a digestive tract tumor to the list of cancers in which this gasdermin may wear a darker hat, at least in part through its influence on the immune landscape.

The clinical implications are twofold. First, GSDME could serve as a prognostic biomarker: measuring its expression in gastric tumor biopsies might help clinicians identify patients at higher risk of progression who warrant closer surveillance or more aggressive treatment. Gastric cancer remains one of the world’s deadliest malignancies, with GLOBOCAN estimates attributing hundreds of thousands of deaths annually to the disease, and prognostic tools that refine risk stratification beyond tumor stage are badly needed. Second, the correlation between GSDME and immune checkpoint molecules raises the possibility that GSDME levels could help predict which patients might benefit from immunotherapy, an approach that has shown mixed results in gastric cancer to date. If high GSDME marks an immunosuppressed yet inflamed tumor, it could flag patients for combination strategies that pair checkpoint blockade with agents that modulate pyroptosis.

The authors caution, implicitly, that correlation in cohort data and knockdown experiments in cell lines do not establish the full mechanism, and the study was supported by grants from the Changshu Science and Technology Project and the Changshu Commission of Health Project, conducted under the Declaration of Helsinki with ethics approval from Affiliated Changshu Hospital of Nantong University. Future work will need to dissect how GSDME reshapes the immune microenvironment in living tumors, whether its pyroptotic or non-pyroptotic functions dominate in gastric cancer, and whether manipulating the protein therapeutically can improve outcomes. For now, the study delivers a clear and consequential message: a protein once celebrated for its ability to detonate cancer cells may, in stomach cancer, be a marker of a tumor that has learned to turn inflammation to its own advantage, and clinicians would do well to pay attention when GSDME levels run high.

Subject of Research: The expression and prognostic role of the pyroptosis protein GSDME in stomach adenocarcinoma and its relationship to the tumor immune microenvironment.

Article Title: GSDME upregulation predicts poor prognosis in gastric cancer

Article References: Xu, Y., Zhuang, Y., Chen, H., Guo, T., Shao, Z., Chen, J., Deng, Y., Zhu, Y., Wan, C., & Gu, Y. (2026). GSDME upregulation predicts poor prognosis in gastric cancer. Molecular Biology Reports, 53(1), Article 1670. https://doi.org/10.1007/s11033-026-12840-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12840-5

Keywords: GSDME, pyroptosis, gastric cancer, stomach adenocarcinoma, prognosis, biomarker, tumor microenvironment, immune checkpoint, TCGA, gasdermin, cell death, immunosuppression